Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Acute Flaccid Myelitis in the United States: 2015-2017.

Ayers T, Lopez A, Lee A, Kambhampati A, Nix WA, Henderson E, Rogers S, Weldon WC, Oberste MS, Sejvar J, Hopkins SE, Pallansch MA, Routh JA, Patel M.

Pediatrics. 2019 Oct 7. pii: e20191619. doi: 10.1542/peds.2019-1619. [Epub ahead of print]

PMID:
31591135
2.

Field Performance of Two Methods for Detection of Poliovirus in Wastewater Samples, Mexico 2016-2017.

Estívariz CF, Pérez-Sánchez EE, Bahena A, Burns CC, Gary HE Jr, García-Lozano H, Rey-Benito G, Peñaranda S, Castillo-Montufar KV, Nava-Acosta RS, Meschke JS, Oberste MS, Lopez-Martínez I, Díaz-Quiñonez JA.

Food Environ Virol. 2019 Sep 30. doi: 10.1007/s12560-019-09399-9. [Epub ahead of print]

PMID:
31571037
3.

Progress Toward Poliovirus Containment Implementation - Worldwide, 2018-2019.

Moffett DB, Llewellyn A, Singh H, Saxentoff E, Partridge J, Iakovenko M, Roesel S, Asghar H, Baig N, Grabovac V, Gurung S, Gumede-Moeletsi N, Barnor J, Theo A, Rey-Benito G, Villalobos A, Boualam L, Swan J, Sutter RW, Pandel E, Wassilak S, Oberste MS, Lewis I, Zaffran M; MEng.

MMWR Morb Mortal Wkly Rep. 2019 Sep 27;68(38):825-829. doi: 10.15585/mmwr.mm6838a3.

4.

Poliopolis: pushing boundaries of scientific innovations for disease eradication.

Van Damme P, Coster I, Bandyopadhyay AS, Suykens L, Rudelsheim P, Neels P, Oberste MS, Weldon WC, Clemens R, Revets H.

Future Microbiol. 2019 Sep 4. doi: 10.2217/fmb-2019-0196. [Epub ahead of print]

5.

Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis.

Mishra N, Ng TFF, Marine RL, Jain K, Ng J, Thakkar R, Caciula A, Price A, Garcia JA, Burns JC, Thakur KT, Hetzler KL, Routh JA, Konopka-Anstadt JL, Nix WA, Tokarz R, Briese T, Oberste MS, Lipkin WI.

MBio. 2019 Aug 13;10(4). pii: e01903-19. doi: 10.1128/mBio.01903-19.

6.

Distinguishing patients with laboratory-confirmed chikungunya from dengue and other acute febrile illnesses, Puerto Rico, 2012-2015.

Alvarado LI, Lorenzi OD, Torres-Velásquez BC, Sharp TM, Vargas L, Muñoz-Jordán JL, Hunsperger EA, Pérez-Padilla J, Rivera A, González-Zeno GE, Galloway RL, Glass Elrod M, Mathis DL, Oberste MS, Nix WA, Henderson E, McQuiston J, Singleton J, Kato C, García-Gubern C, Santiago-Rivera W, Muns-Sosa R, Ortiz-Rivera JD, Jiménez G, Rivera-Amill V, Andújar-Pérez DA, Horiuchi K, Tomashek KM.

PLoS Negl Trop Dis. 2019 Jul 22;13(7):e0007562. doi: 10.1371/journal.pntd.0007562. eCollection 2019 Jul.

7.

The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.

Van Damme P, De Coster I, Bandyopadhyay AS, Revets H, Withanage K, De Smedt P, Suykens L, Oberste MS, Weldon WC, Costa-Clemens SA, Clemens R, Modlin J, Weiner AJ, Macadam AJ, Andino R, Kew OM, Konopka-Anstadt JL, Burns CC, Konz J, Wahid R, Gast C.

Lancet. 2019 Jul 13;394(10193):148-158. doi: 10.1016/S0140-6736(19)31279-6. Epub 2019 Jun 4.

8.

Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.

Snider CJ, Zaman K, Estivariz CF, Yunus M, Weldon WC, Wannemuehler KA, Oberste MS, Pallansch MA, Wassilak SG, Bari TIA, Anand A.

Lancet. 2019 Jun 29;393(10191):2624-2634. doi: 10.1016/S0140-6736(19)30503-3. Epub 2019 May 16.

PMID:
31104832
9.

Picornavirus etiology of acute infections among hospitalized infants.

Abedi GR, Messacar K, Luong W, Nix WA, Rogers S, Queen K, Tong S, Oberste MS, Watt J, Rothrock G, Dominguez S, Gerber SI, Watson JT.

J Clin Virol. 2019 Jul;116:39-43. doi: 10.1016/j.jcv.2019.04.005. Epub 2019 Apr 25.

PMID:
31100674
10.

Extended delivery of vaccines to the skin improves immune responses.

Joyce JC, Sella HE, Jost H, Mistilis MJ, Esser ES, Pradhan P, Toy R, Collins ML, Rota PA, Roy K, Skountzou I, Compans RW, Oberste MS, Weldon WC, Norman JJ, Prausnitz MR.

J Control Release. 2019 Jun 28;304:135-145. doi: 10.1016/j.jconrel.2019.05.006. Epub 2019 May 6. French.

PMID:
31071375
11.

Enterovirus D68-Associated Acute Respiratory Illness - New Vaccine Surveillance Network, United States, July-October, 2017 and 2018.

Kujawski SA, Midgley CM, Rha B, Lively JY, Nix WA, Curns AT, Payne DC, Englund JA, Boom JA, Williams JV, Weinberg GA, Staat MA, Selvarangan R, Halasa NB, Klein EJ, Sahni LC, Michaels MG, Shelley L, McNeal M, Harrison CJ, Stewart LS, Lopez AS, Routh JA, Patel M, Oberste MS, Watson JT, Gerber SI.

MMWR Morb Mortal Wkly Rep. 2019 Mar 29;68(12):277-280. doi: 10.15585/mmwr.mm6812a1. Erratum in: MMWR Morb Mortal Wkly Rep. 2019 Apr 19;68(15):360.

12.

Rapid Disappearance of Poliovirus Type 2 (PV2) Immunity in Young Children Following Withdrawal of Oral PV2-Containing Vaccine in Vietnam.

Huyen DTT, Mach O, Thanh Trung N, Thai PQ, Thang HV, Weldon WC, Oberste MS, Jeyaseelan V, Sutter RW, Anh DD.

J Infect Dis. 2019 Jul 2;220(3):386-391. doi: 10.1093/infdis/jiz124.

PMID:
30869149
13.

Neutralizing Antibody against Enterovirus D68 in Children and Adults before 2014 Outbreak, Kansas City, Missouri, USA1.

Harrison CJ, Weldon WC, Pahud BA, Jackson MA, Oberste MS, Selvarangan R.

Emerg Infect Dis. 2019 Mar;25(3):585-588. doi: 10.3201/eid2503.180960.

14.

Strengthening laboratory surveillance of viral pathogens: Experiences and lessons learned building next-generation sequencing capacity in Ghana.

Marine RL, Ntim NAA, Castro CJ, Attiku KO, Pratt D, Duker E, Agbosu E, Ng TFF, Gatei W, Obodai E, Odoom JK, Walker CL, Rota PA, Oberste MS, Ampofo WK, Balajee SA.

Int J Infect Dis. 2019 Apr;81:231-234. doi: 10.1016/j.ijid.2019.02.008. Epub 2019 Feb 15.

15.

Characterising the costs of the Global Polio Laboratory Network: a survey-based analysis.

Duintjer Tebbens RJ, Diop OM, Pallansch MA, Oberste MS, Thompson KM.

BMJ Open. 2019 Jan 21;9(1):e023290. doi: 10.1136/bmjopen-2018-023290.

16.

Poliovirus Type 2 Seroprevalence Following Full- or Fractional-Dose Inactivated Poliovirus Vaccine in the Period After Sabin Type 2 Withdrawal in Sri Lanka.

Gamage D, Mach O, Ginige S, Weldon WC, Oberste MS, Jeyaseelan V, Sutter RW.

J Infect Dis. 2019 May 24;219(12):1887-1892. doi: 10.1093/infdis/jiz026.

PMID:
30649505
17.

Progress of polio eradication and containment requirements after eradication.

Oberste MS.

Transfusion. 2018 Dec;58 Suppl 3:3078-3083. doi: 10.1111/trf.15018. Review.

PMID:
30536438
18.

In Vitro Antiviral Activity of New Oxazoline Derivatives as Potent Poliovirus Inhibitors.

Madia VN, Messore A, Pescatori L, Saccoliti F, Tudino V, De Leo A, Scipione L, Fiore L, Rhoden E, Manetti F, Oberste MS, Di Santo R, Costi R.

J Med Chem. 2019 Jan 24;62(2):798-810. doi: 10.1021/acs.jmedchem.8b01482. Epub 2018 Dec 18.

PMID:
30512950
19.

Increase in Acute Flaccid Myelitis - United States, 2018.

McKay SL, Lee AD, Lopez AS, Nix WA, Dooling KL, Keaton AA, Spence-Davizon E, Herlihy R, Clark TA, Hopkins SE, Pastula DM, Sejvar J, Oberste MS, Pallansch MA, Patel M, Routh JA.

MMWR Morb Mortal Wkly Rep. 2018 Nov 16;67(45):1273-1275. doi: 10.15585/mmwr.mm6745e1.

20.

Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame.

Gaensbauer JT, Gast C, Bandyopadhyay AS, O'Ryan M, Saez-Llorens X, Rivera L, Lopez-Medina E, Melgar M, Weldon WC, Oberste MS, Rüttimann R, Clemens R, Asturias EJ.

Clin Infect Dis. 2018 Oct 30;67(suppl_1):S57-S65. doi: 10.1093/cid/ciy649.

21.

Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses.

Bhaumik SK, Kulkarni RR, Weldon WC, Silveira ELV, Ahmed H, Gunisetty S, Chandele A, Antia R, Verma H, Sutter R, Pallansch MA, Oberste MS, Villinger F, Orenstein W, Murali-Krishna K.

Clin Infect Dis. 2018 Oct 30;67(suppl_1):S66-S77. doi: 10.1093/cid/ciy634.

22.

Trends in Poliovirus Seroprevalence in Kano State, Northern Nigeria.

Verma H, Iliyasu Z, Craig KT, Molodecky NA, Urua U, Jibir BW, Gwarzo GD, Gajida AU, McDonald S, Weldon WC, Oberste MS, Braka F, Mkanda P, Sutter RW.

Clin Infect Dis. 2018 Oct 30;67(suppl_1):S103-S109. doi: 10.1093/cid/ciy637.

PMID:
30376090
23.

PoSE: visualization of patterns of sequence evolution using PAML and MATLAB.

Zhao K, Henderson E, Bullard K, Oberste MS, Burns CC, Jorba J.

BMC Bioinformatics. 2018 Oct 22;19(Suppl 11):364. doi: 10.1186/s12859-018-2335-7.

24.

Notes from the Field: Enterovirus A71 Neurologic Disease in Children - Colorado, 2018.

Messacar K, Burakoff A, Nix WA, Rogers S, Oberste MS, Gerber SI, Spence-Davizon E, Herlihy R, Dominguez SR.

MMWR Morb Mortal Wkly Rep. 2018 Sep 14;67(36):1017-1018. doi: 10.15585/mmwr.mm6736a5. No abstract available.

25.

Viral Etiology of Acute Gastroenteritis in <2-Year-Old US Children in the Post-Rotavirus Vaccine Era.

Hassan F, Kanwar N, Harrison CJ, Halasa NB, Chappell JD, Englund JA, Klein EJ, Weinberg GA, Szilagyi PG, Moffatt ME, Oberste MS, Nix WA, Rogers S, Bowen MD, Vinjé J, Wikswo ME, Parashar UD, Payne DC, Selvarangan R.

J Pediatric Infect Dis Soc. 2018 Sep 3. doi: 10.1093/jpids/piy077. [Epub ahead of print]

PMID:
30184153
26.

Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine.

Gamage D, Mach O, Palihawadana P, Zhang Y, Weldon WC, Oberste MS, Gunasena S, Sutter RW.

J Infect Dis. 2018 Nov 5;218(12):1876-1882. doi: 10.1093/infdis/jiy389.

PMID:
29982532
27.

Enterovirus and Parechovirus Surveillance - United States, 2014-2016.

Abedi GR, Watson JT, Nix WA, Oberste MS, Gerber SI.

MMWR Morb Mortal Wkly Rep. 2018 May 11;67(18):515-518. doi: 10.15585/mmwr.mm6718a2.

28.

Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial.

Zaman K, Estívariz CF, Morales M, Yunus M, Snider CJ, Gary HE Jr, Weldon WC, Oberste MS, Wassilak SG, Pallansch MA, Anand A.

Lancet Infect Dis. 2018 Jun;18(6):657-665. doi: 10.1016/S1473-3099(18)30113-0. Epub 2018 Mar 20.

PMID:
29571817
29.

Assessment of poliovirus antibody seroprevalence in high risk areas for vaccine derived poliovirus transmission in Madagascar.

Razafindratsimandresy R, Mach O, Heraud JM, Bernardson B, Weldon WC, Oberste MS, Sutter RW.

Heliyon. 2018 Mar 7;4(3):e00563. doi: 10.1016/j.heliyon.2018.e00563. eCollection 2018 Mar.

30.

Assessing the potency and immunogenicity of inactivated poliovirus vaccine after exposure to freezing temperatures.

White JA, Estrada M, Weldon WC, Chumakov K, Kouiavskaia D, Fournier-Caruana J, Stevens E, Gary HE Jr, Maes EF, Oberste MS, Snider CJ, Anand A, Chen D.

Biologicals. 2018 May;53:30-38. doi: 10.1016/j.biologicals.2018.03.002. Epub 2018 Mar 14.

31.

Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017.

Hussain I, Mach O, Hamid NA, Bhatti ZS, Moore DD, Oberste MS, Khan S, Khan H, Weldon WC, Sutter RW, Bhutta ZA, Soofi SB.

Vaccine. 2018 Apr 5;36(15):1921-1924. doi: 10.1016/j.vaccine.2018.02.055. Epub 2018 Mar 3.

32.

The seasonality of nonpolio enteroviruses in the United States: Patterns and drivers.

Pons-Salort M, Oberste MS, Pallansch MA, Abedi GR, Takahashi S, Grenfell BT, Grassly NC.

Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):3078-3083. doi: 10.1073/pnas.1721159115. Epub 2018 Mar 5.

33.

Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan.

Saleem AF, Yousafzai MT, Mach O, Khan A, Quadri F, Weldon WC, Oberste MS, Zaidi SS, Alam MM, Sutter RW, Zaidi AKM.

Vaccine. 2018 Mar 20;36(13):1766-1771. doi: 10.1016/j.vaccine.2018.02.051. Epub 2018 Feb 21.

34.

Dynamics of Evolution of Poliovirus Neutralizing Antigenic Sites and Other Capsid Functional Domains during a Large and Prolonged Outbreak.

Shaw J, Jorba J, Zhao K, Iber J, Chen Q, Adu F, Adeniji A, Bukbuk D, Baba M, Henderson E, Dybdahl-Sissoko N, McDonald S, Weldon WC, Gumede N, Oberste MS, Kew OM, Burns CC.

J Virol. 2018 Apr 13;92(9). pii: e01949-17. doi: 10.1128/JVI.01949-17. Print 2018 May 1.

35.

Assessment of poliovirus antibody seroprevalence in polio high risk areas of West Africa.

Guindo O, Mach O, Doumbia S, Ekra DK, Beavogui AH, Weldon WC, Oberste MS, Sutter RW.

Vaccine. 2018 Feb 14;36(8):1027-1031. doi: 10.1016/j.vaccine.2018.01.022. Epub 2018 Jan 19.

PMID:
29358054
36.

Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.

Brickley EB, Strauch CB, Wieland-Alter WF, Connor RI, Lin S, Weiner JA, Ackerman ME, Arita M, Oberste MS, Weldon WC, Sáez-Llorens X, Bandyopadhyay AS, Wright PF.

J Infect Dis. 2018 Jan 17;217(3):371-380. doi: 10.1093/infdis/jix556.

37.

Diagnostic Assay Development for Poliovirus Eradication.

Gerloff N, Sun H, Mandelbaum M, Maher C, Nix WA, Zaidi S, Shaukat S, Seakamela L, Nalavade UP, Sharma DK, Oberste MS, Vega E.

J Clin Microbiol. 2018 Jan 24;56(2). pii: e01624-17. doi: 10.1128/JCM.01624-17. Print 2018 Feb.

38.

Severe Respiratory Illness Associated With Rhinovirus During the Enterovirus D68 Outbreak in the United States, August 2014-November 2014.

Prill MM, Dahl RM, Midgley CM, Chern SW, Lu X, Feikin DR, Sakthivel SK, Nix WA, Watson JT, Gerber SI, Oberste MS.

Clin Infect Dis. 2018 May 2;66(10):1528-1534. doi: 10.1093/cid/cix1034.

PMID:
29186347
39.

Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules.

Bandyopadhyay AS, Asturias EJ, O'Ryan M, Oberste MS, Weldon W, Clemens R, Rüttimann R, Modlin JF, Gast C.

Vaccine. 2017 Dec 19;35(52):7283-7291. doi: 10.1016/j.vaccine.2017.11.006. Epub 2017 Nov 14.

40.

High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses.

Muller DA, Fernando GJP, Owens NS, Agyei-Yeboah C, Wei JCJ, Depelsenaire ACI, Forster A, Fahey P, Weldon WC, Oberste MS, Young PR, Kendall MAF.

Sci Rep. 2017 Oct 3;7(1):12644. doi: 10.1038/s41598-017-13011-0.

41.

Survey of poliovirus antibodies in Borno and Yobe States, North-Eastern Nigeria.

Gofama MM, Verma H, Abdullahi H, Molodecky NA, Craig KT, Urua UA, Garba MA, Alhaji MA, Weldon WC, Oberste MS, Braka F, Muhammad AJG, Sutter RW.

PLoS One. 2017 Sep 26;12(9):e0185284. doi: 10.1371/journal.pone.0185284. eCollection 2017.

42.

Clinical and epidemiologic characteristics of dengue and other etiologic agents among patients with acute febrile illness, Puerto Rico, 2012-2015.

Tomashek KM, Lorenzi OD, Andújar-Pérez DA, Torres-Velásquez BC, Hunsperger EA, Munoz-Jordan JL, Perez-Padilla J, Rivera A, Gonzalez-Zeno GE, Sharp TM, Galloway RL, Glass Elrod M, Mathis DL, Oberste MS, Nix WA, Henderson E, McQuiston J, Singleton J, Kato C, García Gubern C, Santiago-Rivera W, Cruz-Correa J, Muns-Sosa R, Ortiz-Rivera JD, Jiménez G, Galarza IE, Horiuchi K, Margolis HS, Alvarado LI.

PLoS Negl Trop Dis. 2017 Sep 13;11(9):e0005859. doi: 10.1371/journal.pntd.0005859. eCollection 2017 Sep.

43.

Complete Genome Sequences of Mumps and Measles Virus Isolates from Three States in the United States.

Magaña LC, Espinosa A, Marine RL, Ng TFF, Castro CJ, Montmayeur AM, Hacker JK, Scott S, Whyte T, Bankamp B, Oberste MS, Rota PA.

Genome Announc. 2017 Aug 17;5(33). pii: e00748-17. doi: 10.1128/genomeA.00748-17.

44.

Seroprevalence of Anti-polio Antibodies in Children From Polio High-risk Areas of Pakistan: A Cross-Sectional Survey 2015-2016.

Hussain I, Mach O, Habib A, Bhatti Z, Suhag Z, Oberste MS, Weldon WC, Sutter RW, Soofi SB, Bhutta ZA.

Pediatr Infect Dis J. 2017 Sep;36(9):e230-e236. doi: 10.1097/INF.0000000000001622.

PMID:
28806355
45.

Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan.

Saleem AF, Mach O, Yousafzai MT, Khan A, Weldon WC, Oberste MS, Sutter RW, Zaidi AKM.

Vaccine. 2017 May 31;35(24):3209-3214. doi: 10.1016/j.vaccine.2017.04.075. Epub 2017 May 4.

46.

Nonspecific Effects of Oral Polio Vaccine on Diarrheal Burden and Etiology Among Bangladeshi Infants.

Upfill-Brown A, Taniuchi M, Platts-Mills JA, Kirkpatrick B, Burgess SL, Oberste MS, Weldon W, Houpt E, Haque R, Zaman K, Petri WA Jr.

Clin Infect Dis. 2017 Aug 1;65(3):414-419. doi: 10.1093/cid/cix354.

47.

Enterovirus D68 Infection Among Children With Medically Attended Acute Respiratory Illness, Cincinnati, Ohio, July-October 2014.

Biggs HM, McNeal M, Nix WA, Kercsmar C, Curns AT, Connelly B, Rice M, Chern SW, Prill MM, Back N, Oberste MS, Gerber SI, Staat MA.

Clin Infect Dis. 2017 Jul 15;65(2):315-323. doi: 10.1093/cid/cix314.

48.

Severe Parechovirus 3 Infections in Young Infants-Kansas and Missouri, 2014.

Midgley CM, Jackson MA, Selvarangan R, Franklin P, Holzschuh EL, Lloyd J, Scaletta J, Straily A, Tubach S, Willingham A, Nix WA, Oberste MS, Harrison CJ, Hunt C, Turabelidze G, Gerber SI, Watson JT.

J Pediatric Infect Dis Soc. 2018 May 15;7(2):104-112. doi: 10.1093/jpids/pix010.

49.

Genomic Characterization of Three Melon Necrotic Spot Viruses Detected in Human Stool Specimens.

Marine R, Castro C, Magaña L, Ng TF, Aswath K, Collins N, Park GW, Vinjé J, Oberste MS.

Genome Announc. 2017 Mar 16;5(11). pii: e01758-16. doi: 10.1128/genomeA.01758-16.

50.

Seroprevalence of poliovirus antibodies in the Kansas City metropolitan area, 2012-2013.

Wallace GS, Pahud BA, Weldon WC, Curns AT, Oberste MS, Harrison CJ.

Hum Vaccin Immunother. 2017 Apr 3;13(4):776-783. doi: 10.1080/21645515.2016.1255386. Epub 2017 Jan 6.

Supplemental Content

Loading ...
Support Center